2020 Alzheimer's Association International Conference (AAIC)
Virtual Meeting (July 27-31, 2020)

• Sood A, Pavlik VN, Darby E, Chan W, Doody R. Different profiles of cognitive deficits predict progression rate in probable AD. Presented at the 2020 Alzheimer's Association International Conference (AAIC), Virtual Meeting (July 27-31, 2020).  

American Academy of Neurology (AAN)
71^st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)

• Klein G, Delmar P, Rehal S, Adjelkovic M, Abi-Saab D, Bullain SS, et al. Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies. Neurology. 2019;92(15 Suppl):S9.007. [Platform Presentation] 
• Sink S, Ostrowitzki S, Millar L, Warren F, Lin HC, Smith J, et al. Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer's disease (CREAD). Neurology. 2019;92(15 Suppl):P4.1-002. 

2018 Alzheimer's Association International Conference (AAIC)
Chicago, Ill. (July 22-26, 2018)

• Abi-Saab D, Andjelkovic M, Pross N, Delmar P, Voyle N, Klein G, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road Study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration. Alzheimers Dement. 2018;14(7 Suppl):P241. 
• Andjelkovic M, Abi-Saab D, Delmar P, Pross N, Voyle N, Klein G, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road Study in patients with prodromal Alzheimer's disease after approximately two years of study duration. Alzheimers Dement. 2018;14(7 Suppl):P241-P242. 
• Burham, SC, Colom PM, Datigues JF, Doody R, Hansson O, et al. Concord-AD: An international network of cohorts for better understanding of Alzheimer's disease. Alzheimers Dement. 2018;14(7 Suppl):P1465. 
• Klein G, Delmar P, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, et al. Twenty-four month amyloid PET results of the gantenerumab high dose open label extension studies. Alzheimers Dement. 2018;14(7 Suppl):P240-P241. 
• Lin H, Ostrowitzki S, Sink KM, Millar L, Warren F, Smith J, et al. Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD). Alzheimers Dement. 2018;14(7 Suppl):P217. 
• Voyle N, Abi-Saab D, Klein G, Hofmann C, Delmar P, Pross N, et al. The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite Road Study. Alzheimers Dement. 2018;14(7 Suppl):P240. 

American Academy of Neurology (AAN)
70^th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

• Klein G, Delmar P, Hofmann C, Adjelkovic M, Abi-Saab D, Milosavljevic-Ristic S, et al. Higher dose gantenerumab leads to significant reduction in amyloid plaque burden - Results for the Marguerite and Scarlet Road open label extension studies. Neurology. 2018;90(15 Suppl):S2.005. 

International Neuropsychological Society (INS)
45^th Annual Meeting in New Orleans, La. (Feb. 1-7, 2017)

• Alverson WA, Massman PJ, Doody RS. Longitudinal cognitive asymmetry and decline in Alzheimer's disease patients. J Int Neuropsychol Soc. 2017;23(Suppl S1):217-8. 

2016 Alzheimer's Association International Conference (AAIC)
Toronto, Canada (July 22-28, 2016)

• Margolin RA, Schneider LS, Cutter GR, Breitner JCS, Doody RS, Landreth G, et al. Advancing therapeutics for neuroinflammation in Alzheimer's disease: Clinical development considerations. Alzheimers Dement. 2016;12(7 Suppl):P822. 

American Academy of Neurology (AAN)
68^th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)

• Siffert J, Hammond F, Alexander D, Cutler A, D'Amico S, Doody R, et al. PRISM II: Effectiveness of dextromethorphan 20 mg/quinidine 10 mg (Nuedexta®) for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Combined results of a multicenter open-label study. Neurology. 2016;86(Meeting Abstracts 1):P2.225. 
• Viglietta V, O'Gorman J, Williams L, Tian Y, Sandrock A, Doody R, et al. Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design. Neurology. 2016;86(Meeting Abstracts 1):S1.003. [Oral Presentation] 

Society for Neuroscience (SFN)
45^th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2015)

• Lazar E, Woodward M, Amrutkar C, Hagemeier J, Shah H, Benedict R, et al. Validation of olfactory identification deficit as a biomarker of Alzheimer's disease. Program No. 622.14. 2015 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2015. Online. 

2015 Alzheimer's Association International Conference (AAIC)
Washington, DC (July 18-23, 2015)

• Doody RS, Cutler AJ, D'Amico S, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Comparison of patient-reported ratings to those of caregiver proxies in a 12-week open-label trial (PRISM II). Alzheimers Dement. 2015;11(7 Suppl):P471.  [View poster]
• Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of CNS-LS outcomes in a 12-week open-label trial (PRISM II). Alzheimers Dement. 2015;11(7 Suppl):P743.  [View poster]
• Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect in patients with dementia: Treatment effects by concomitant antidepressant use in a 12-week open-label trial (PRISM II). Alzheimers Dement. 2015;11(7 Suppl):P292. [Platform Presentation]  [View poster]
• Sabbagh MN, Burstein A, Grimes I, Valcarce C, Doody RS, Sano M, et al. TTP488 path to registration: Leveraging enrichment strategies. Alzheimers Dement. 2015;11(7 Suppl):P758. 
• Sabbagh MN, Burstein A, Grimes I, Valcarce C, Rose E, Doody RS, et al. TTP488: From futile to fast track. Alzheimers Dement. 2015;11(7 Suppl):P290. 

American Academy of Neurology (AAN)
67^th Annual Meeting in Washington, DC (April 18-25, 2015)

• Amrutkar C, Woodward M, Shah H, Benedict R, Rajakrishnan S, Doody R, et al. Validation of olfactory deficit as a biomarker of Alzheimer's disease. Neurology. 2015;84(Meeting Abstracts 1):P2.170.  [View poster]
• Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. PRISM II: An open-label study to assess the safety, tolerability, and effectiveness of dextromethorphan 20 mg/quinidine 10 mg for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Results from the Alzheimer's disease/dementia cohort. Neurology. 2015;84(Meeting Abstracts 1):P7.109.  [View poster]

American Neurological Association (ANA)
139^th Annual Meeting in Baltimore, Md. (Oct. 12-14, 2014)

• Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. WIP safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's disease/dementia: PRISM-II. Ann Neurol. 2014;76 Suppl 18: S99-100. 
• Majid T, Chan W, Darby E, Pavlik V, Doody R. Antioxidant biomarkers predict annualized change in MMSE score in MCI and AD patients in the TARCC cohort. Ann Neurol. 2014;76 Suppl 18:S94-5. 

2014 Alzheimer's Association International Conference (AAIC)
Copenhagen, Denmark (July 12-17, 2014)

• Grill JD, Raman R, Ernstrom K, Dowsett S, Chen Y-F, Liu-Seifert H, et al. Comparing recruitment among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Dement. 2014;10(4 Suppl):P852-P853.  [View poster]
• Henley DB, Dowsett SA, Chen Y-F, Liu-Seifert H, Grill JD, Doody R, et al. Regional variation in Alzheimer's disease progression in a clinical trial setting. Alzheimers Dement. 2014;10(4 Suppl):P821.  [View poster]

International Neuropsychological Society (INS)
42^nd Annual Meeting in Seattle, Wash. (Feb. 12-15, 2014)

• Alverson WA, Massman PJ, Grabyan JM, Doody RS. Progression and stability of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Int Neuropsychol Soc. 2014;20(Suppl S1):159-60. 

2013 Alzheimer's Association International Conference (AAIC)
Boston, Mass. (July 13-18, 2013)

• Doody R, Cutler A, D'Amico S, Zorowitz R, Alexander D, Hammond F, et al. A study to assess the safety, tolerability, and effectiveness of Nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II]. Alzheimers Dement. 2013;9(4 Suppl):P662.  [View poster]
• Szigeti K, Trummer B, Lal D, Yan L, Song L, Doody R. Ordered subset analysis CNV association with Alzheimer's disease AAO phenotypes. Alzheimers Dement. 2013;9(4 Suppl):P176-P177. 

American Academy of Neurology (AAN)
65^th Annual Meeting in San Diego, Calif. (March 16-23, 2013)

• Biernot J, Darby E, Chan W, Pavlik V, Doody R. Examining anti-dementia drug persistence in Alzheimer's disease (AD) patients. Neurology. 2013;80(Meeting Abstracts 1):P07.140.  [View poster]

International Neuropsychological Society (INS)
41^st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)

• Grabyan JM, Massman PJ, Alverson W, Doody RS. A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients. J Int Neuropsychol Soc. 2013;19(Suppl S1):214. 
• Lowe DA, Balsis S, Miller T, Benge JF, Doody RS. Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes. J Int Neuropsychol Soc. 2013;19(Suppl S1):128-9. 

American Neurological Association (ANA)
137^th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)

• Szigeti K, Lal D, Li Y, Doody RS, Yan L. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. Ann Neurol. 2012;72 Suppl 16:S134-5. [Platform Presentation] 

Alzheimer's Association International Conference (AAIC)
Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012)

• Doody R, Chan W, Pavlik V, Rountree S, Massman P. Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures. Alzheimers Dement. 2012;8(4 Suppl):P455. 
• McGee JS, Nguyen A, Darby E, Chan W, Pavlik V, Doody R. Factors influencing time to nursing home placement in persons with probable Alzheimer's disease. Alzheimers Dement. 2012;8(4 Suppl):P374.  [View poster]
• Rountree S, Chan W, Pavlik V, Doody R. Factors that influence long term care placement in an Alzheimer disease cohort. Alzheimers Dement. 2012;8(4 Suppl):P375.  [View poster]
• Szigeti K, Li Y, Shaw C, Sheffer I, Sule N, Powell S, et al. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Alzheimers Dement. 2012;8(4 Suppl):P672. 
• Winblad B, Doody R, Cummings J, Tariot P, Sano M, Aisen P, et al. Dimebon in Alzheimer's disease: Summary and contract of three efficacy trials. Alzheimers Dement. 2012;8(4 Suppl):P456. 

International Neuropsychological Society (INS)
40^th Annual Meeting in Montreal, Quebec, Canada (Feb. 15-18, 2012)

• Grabyan JM, Massman PJ, Porter B, Doody RS. Plasma cortisol does not predict rate of cognitive decline in Alzheimer's patients. J Int Neuropsychol Soc. 2012;18(Suppl S1):263.  [View poster]
• McGee JS, Darby EJ, Biernot J, Doody RS. Amnestic MCI, sleep disturbance, and cognitive functioning. J Int Neuropsychol Soc. 2012;18(Suppl S1):277.  [View poster]

2011 International Conference on Alzheimer's Disease (ICAD)
Paris, France (July 16-21, 2011)

• Barber R, O'Bryant S, Reisch J, Doody R, Fairchild T, Adams P, et al. Serum granulocyte colony stimulating factor and Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S313.  [View poster]
• Dentino A, Hall J, Barber R, Doody R, Royall D, O'Bryant S. The impact of depression on cognition varies by APOE4 status. Alzheimers Dement. 2011;7(4 Suppl):S350. 
• Doody R, Chan W, Ballantyne C, Pavlik V, Barber R, O'Bryant S, et al. Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine. Alzheimers Dement. 2011;7(4 Suppl):S317-S8.  [View poster]
• Doody R, Chan W, Barber R, Ballantyne C, Pavlik V, O'Bryant S, et al. Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort. Alzheimers Dement. 2011;7(4 Suppl):S318.  [View poster]
• Mielke M, Haughey N, Bandaru VVR, Weinberg D, Zaidi N, Pavlik V, et al. Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S322-S3. 
• O'Bryant S, Xiao G, Barber R, Hall J, Doody R, Reisch J, et al. Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S325. 
• O'Bryant S, Xiao G, Robert B, Hall J, Doody R, Reisch J, et al. A serum protein-based algorithm for the detection of Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S674-S5. 
• Pavlik V, Massman P, Rustveld L, Doody R. Racial/ethnic group differences in the association of APOE ε4 genotype and visuospatial test performance in a non-demented sample. Alzheimers Dement. 2011;7(4 Suppl):S361. 
• Rountree S, Chan W, Pavlik V, Darby E, Doody R. Factors that influence survival in Alzheimer's patients. Alzheimers Dement. 2011;7(4 Suppl):S513. 
• Royall DR, Doody R, Barber R, Palmer R, O'Bryant S, Reisch J, et al. The cognitive correlates of functional status: a new approach to dementia. Alzheimers Dement. 2011;7(4 Suppl):S175. 
• Wilhelmsen K, Chasse S, Griffin N, Diaz-Arrastia R, Barber R, Royall D, et al. Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S335-S6. 
• Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, et al. Developing and validating of diagnostic algorithm for Alzheimer's disease. Alzheimers Dement. 2011;7(4 Suppl):S334-S5. 

American Academy of Neurology (AAN)
63^rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

• Doody RS, Ramos H, Faison W, Zou H. Efficacy and safety of donepezil 23 mg/day in patients with moderate-to-severe Alzheimer's disease with concomitant memantine use. Neurology. 2011;76(Suppl 4):A619-20.  [View poster]
• Pavlik V, Massman P, Ballantyne C, Barber R, Doody RS. Differences in the association of peripheral insulin and cognitive function in non-diabetic ad cases and normal controls. Neurology. 2011;76(Suppl 4):A122.  [View poster]

International Neuropsychological Society (INS)
39^th Annual Meeting in Boston, Mass. (Feb. 2-5, 2011)

• Havins W, Harika L, Massman PJ, Doody RS. Differential recall of nouns and verbs in patients with probable Alzheimer's disease (AD). J Int Neuropsychol Soc. 2011;17(Suppl S1):75.  [View poster]
• Havins WN, Agbayani KA, Massman PJ, Doody RS. Cognitive reserve as a moderator for the relationship between depression and cognitive functioning in Alzheimer's disease. J Int Neuropsychol Soc. 2011;17(Suppl S1):75.  [View poster]
• Massman PJ, Burrows C, Hall J, Doody RS. Cortisol levels in Alzheimer's patients are related to premorbid functioning and rate of progression. J Int Neuropsychol Soc. 2011;17(Suppl S1):77.  [View poster]

2010 International Conference on Alzheimer's Disease (ICAD)
Honolulu, Hawaii (July 10-15, 2010)

• Barber R, Xiao G, O'Bryant S, Saunders J, Reisch J, Doody R, et al. An inflammatory endophenotype of Alzheimer's disease. Alzheimers Dement. 2010;6(4 Suppl):S530.  [View poster]
• Chan M, Pavlik VN, Chan W, Darby E, Khaleeq A, Doody RS. Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology. Alzheimers Dement. 2010;6(4 Suppl):S460.  [View poster]
• Diaz-Arrastia R, Xiao G, Reisch J, Barber R, Doody R, Fairchild T, et al. A serum protein-based diagnostic algorithm for Alzheimer's disease. Alzheimers Dement. 2010;6(4 Suppl):S130. 
• Doody RS, Tariot P, Cummings J, Winblad B, Selby B, Langenberg A, et al. Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2010;6(4 Suppl):S147. 
• Huebinger RM, Wilhelmsen K, Diaz-Arrastia R, Chasse S, O'Bryant SE, Doody R, et al. Association of genetic variation in the electron transport chain and Alzheimer's disease. Alzheimers Dement. 2010;6(4 Suppl):S195-S196.  [View poster]
• Wilhelmsen KC, Chasse SA, Gizer IR, Cameron NG, Ellis JW, Diaz-Arrastia R, et al. Genome-wide association scan for biomarker endophenotypes of Alzheimer's disease. Alzheimers Dement. 2010;6(4 Suppl):S129. 

American Academy of Neurology (AAN)
61^st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)

• Benge J, Balsis S, Geraci L, Massman P, Doody R. How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis. Neurology. 2009;72(11 Suppl 3):A247.  [View poster]
• Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, et al. Age at onset and pre- morbid IQ influence early progression rates in AD. Neurology. 2009;72(11 Suppl 3):A478.  [View poster]

International Neuropsychological Society (INS)
37^th Annual Meeting in Atlanta, Ga. (Feb. 11-14, 2009)

• Massman P, Doody RS. Significance of the apolipoprotein E ε2 allele in Alzheimer's patients' memory functioning. J Int Neuropsychol Soc. 2009;15(Suppl S1):202.  [View poster]

2008 International Conference on Alzheimer's Disease (ICAD)
Chicago, Ill. (July 26-31, 2008)

• Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, et al. Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia. 2008;4(4 Suppl):T770-1.  [View poster]
• Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, et al. Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting. Alzheimer's & Dementia. 2008;4(4 Suppl):T263.  [View poster]
• Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, et al. Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study. Alzheimer's & Dementia. 2008;4(4 Suppl):T771.  [View poster]
• Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R. The effects of donepezil on Alzheimer's disease progression monitored by MRI. Alzheimer's & Dementia. 2008;4(4 Suppl):T55.  [View poster]
• Rountree S, Pavlik V, Chan W, Doody RS. Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort. Alzheimer's & Dementia. 2008;4(4 Suppl):T698-9.  [View poster]
• Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype. Presented at the 2008 International Conference on Alzheimer's Disease (ICAD), Chicago, Ill. (July 26-31, 2008).   [View poster]

American Academy of Neurology (AAN)
60^th Annual Meeting in Chicago, Ill. (April 12-19, 2008)

• Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, et al. Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting. Neurology. 2008;70(11 Suppl 1):A147.  [View poster]
• Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M. Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results. Neurology. 2008;70(11 Suppl 1):A98. 
• Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L. Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study. Neurology. 2008;70(11 Suppl 1):A393-4. 
• Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an AD cohort. Neurology. 2008;70(11 Suppl 1):A146.  [View poster]

American Neurological Association (ANA)
132^nd Annual Meeting in Washington, DC (Oct. 7-10, 2007)

• Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, et al. Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD). Ann Neurol. 2007;62 Suppl 11:S55.  [View poster]

Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2007)

• Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, et al. Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease. Alzheimers Dement. 2007;3(3 Suppl):S199-200.  [View poster]
• Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, et al. Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics. Alzheimers Dement. 2007;3(3 Suppl):S192-3. 
• Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS. Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD). Alzheimers Dement. 2007;3(3 Suppl):S130.  [View poster]
• Senanarong V, Hamphadungkit K, Poungvarin N, Cummings J, Doody R. The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly. Alzheimers Dement. 2007;3(3 Suppl):S178. 

American Academy of Neurology (AAN)
59^th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)

• Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, et al. Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study. Neurology. 2007;68(12 Suppl 1):A353. 

8^th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

• Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, et al. Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe). Neurodegener Dis. 2007;4 Suppl 1:333. 

10^th International Conference on Alzheimer's Disease and Related Disorders
Madrid, Spain (July 15-20, 2006)

• Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, et al. Predicting progression and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S83. 
• Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? Alzheimer's & Dementia. 2006;2(3 Suppl):S263.  [View poster]
• Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS. Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes. Alzheimer's & Dementia. 2006;2(3 Suppl):S269.  [View poster]
• Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W. Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease. Alzheimer's & Dementia. 2006;2(3 Suppl):S159.  [View platform presentation]

American Academy of Neurology (AAN)
58^th Annual Meeting in San Diego, Calif. (April 1-8, 2006)

• Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Neurology. 2006;66(5 Suppl 2):A347.  [View poster]

American Heart Association/National Heart, Lung, and Blood Institute
46^th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in Phoenix, Ariz. (March 2-5, 2006)

• Pavlik VN, Hyman DJ, Balasubramanyam A, Doody R. Association between cognitive function and metabolic control parameters in treated patients with type 2 diabetes. Circulation. 2006;113(8):e342. 

International Neuropsychological Society (INS)
34^th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)

• Acharya D, Massman P, Doody R. Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients. Int J Neurosci. 2006;12(Suppl S1):47. 
• Benge J, Massman P, Jenkins R, Thornton G, Doody R. Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease. Int J Neurosci. 2006;12(Suppl S1):55.  [View poster]
• Jenkins R, Massman P, Benge J, Thornton G, Doody R. Naming improvement with phonemic cues: Which Alzheimer's patients benefit most? Int J Neurosci. 2006;12(Suppl S1):51.  [View poster]
• Thornton G, Massman P, Benge J, Jenkins R, Doody R. Category-letter fluency discrepancies in healthy older adults: Normative data and reliability. Int J Neurosci. 2006;12(Suppl S1):192.  [View poster]

American Neurological Association (ANA)
130^th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)

• Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Ann Neurol. 2005;58 Suppl 9:S49-50. 

2^nd Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2005)

• Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Alzheimers Dement. 2005;1(1 Suppl):S67. 
• Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, et al. Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis. Alzheimers Dement. 2005;1(1 Suppl):S93. 

American Academy of Neurology (AAN)
57^th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)

• Issa A, Rountree S, Waring S, Yeh S, Doody RS. Mild cognitive impairment types and their outcomes. Neurology. 2005;64(6 Suppl 1):A168. 
• Massman P, Doody RS. ADAS-Cog change rates in MMSE Strata relevant to clinical trials. Neurology. 2005;64(6 Suppl 1):A70. 
• Pavlik V, Doody RS, Massman P, Chan W, Yeh S. Relationship of premorbid IQ and education to progression of Alzheimer's disease. Neurology. 2005;64(6 Suppl 1):A317.  [View poster]

European Federation of Neurological Societies (EFNS)
8^th Congress in Paris, France (Sept. 4-7, 2004)

• Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H. Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day. Eur J Neurol. 2004;11(Suppl 2):44. 
• Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A. Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Eur J Neurol. 2004;11(Suppl 2):193. 

9^th International Conference on Alzheimer's Disease and Related Disorders
Philadelphia, Penn. (July 17-22, 2004)

• Doody R, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. Neurobiol Aging. 2004;25 Suppl 2:S469-70. 
• Massman P, Doody R. Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients. Neurobiol Aging. 2004;25 Suppl 2:S120. 
• Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, et al. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary. Neurobiol Aging. 2004;25 Suppl 2:S99-100. 
• Wirth Y, Doody RS, Schmitt FA, Mobius HJ. Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. Neurobiol Aging. 2004;25 Suppl 2:S205. 

XXIV^th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress
Paris, France (June 20-24, 2004)

• Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A. Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease. Int J Neuropsychopharmacol. 2004;7 Suppl 2:S207. 

American Academy of Neurology (AAN)
55^th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

• Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 VaD Study Groups. Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia. Neurology. 2003;60(5 Suppl 1):A412. 
• Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ. Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease. Neurology. 2003;60(5 Suppl 1):A414. 

8^th International Conference on Alzheimer's Disease and Related Disorders
Stockholm, Sweden (July 20-25, 2002)

• Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, et al. How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses? Neurobiol Aging. 2002;23(1 Suppl):S274. 
• Doody RS. Pathogenesis and treatment strategies for selected therapies under development. Neurobiol Aging. 2002;23(1 Suppl):S144. 
• Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S. Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease. Neurobiol Aging. 2002;23(1 Suppl):S555. 

Society for Epidemiologic Research (SER)
35^th Annual Meeting in Palm Desert, Calif. (June 19-21, 2002)

• Pavlik VN, Hyman DJ, Doody R. Cognitive function and cardiovascular risk factors in adults 30-59 years old (NHANES III). Am J Epidemiol. 2002;155(Suppl):S24. 

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Denver, Colo. (April 19, 2002)

• Waring S, Doody RS. Survival in patients with dementia from a large multi ethnic population. Neuroepidemiology. 2002;21:211. 

International Neuropsychological Society (INS)
30^th Annual Meeting in Toronto, Canada (Feb. 13-16, 2002)

• Davis R, Atchison T, Massman P, Doody R. Growth curve analysis of decline in instrumental activities of daily living in AD patients. J Int Neuropsychol Soc. 2002;8:266. 
• Davis R, Massman P, Doody R. Measurement invariance of the WAIS-R in AD among patients at higher versus lower levels of dementia severity. J Int Neuropsychol Soc. 2002;8:158. 
• Davis R, Massman P, Doody R. WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability. J Int Neuropsychol Soc. 2002;8:265. 

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Philadelphia, Penn. (May 9, 2001)

• Waring S, Doody RS. Racial differences among patients with Alzheimer's disease from a large multi ethnic population. Neuroepidemiology. 2001;20:118. 

American Academy of Neurology (AAN)
53^rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)

• Doody RS, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease. Neurology. 2001;56(8 Suppl 3):A456. 

7^th International Conference on Alzheimer's Disease and Related Disorders
Washington, DC (July 9-18, 2000)

• Doody RS. Cholinesterase inhibitors: Benefits and limitations. Neurobiol Aging. 2000;21(1 Suppl):S8. 

American Academy of Neurology (AAN)
52^nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)

• Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study. Neurology. 2000;54(Suppl 3):A415. 
• Sumaira R, Doody R, Lai EC. Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden. Neurology. 2000;54(Suppl 3):A417. 

American Society of Consultant Pharmacists (ASCP)
30^th Annual Meeting in St. Loius, Mo. (Nov. 10-13, 1999)

• Doody R, Geldmacher DS, Pratt RD, Perdoma CA. Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety. Consult Pharm. 1999;14(10):1142. 

European College of Neuropsychopharmacology (ECNP)
12^th Congress in London, United Kingdom (Sept. 21-25, 1999)

• Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study. Eur Neuropsychopharmacol. 1999;9 Suppl 5:S328. 

European Neurological Society (ENS)
9^th Annual Meeting in Milan, Italy (June 5-9, 1999)

• Doody RS, Geldmacher DS, Pratt RD, Perdomo CA. Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration. J Neurol. 1999;246 Suppl 1:I52. 

American Academy of Neurology (AAN)
51^st Annual Meeting in Toronto, Canada (April 17-24, 1999)

• Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y. Does ApoE4 correlate with MRI changes in Alzheimer's disease? Neurology. 1999;52(Suppl 2):A366. 
• Doody RS, Pratt R, Perdomo C. Clinical benefits of donepezil: Results from a long-term phase III extension trial. Neurology. 1999;52(Suppl 2):A174. 

European College of Neuropsychopharmacology (ECNP)
11^th Congress in Paris, France (Oct. 31 - Nov. 4, 1998)

• Petit H, Doody RS, Pratt R. Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials. Eur Neuropsychopharmacol. 1998;8 Suppl 2:S274. 

6^th International Conference on Alzheimer's Disease and Related Disorders
Amsterdam, The Netherlands (July 18-23, 1998)

• Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients. Neurobiol Aging. 1998;19(Suppl 45):S303. 
• Kataki M, Doody RS, Liao J, Sims J. The presence of APO E4 does not influence rate of decline in Alzheimer's disease. Neurobiol Aging. 1998;19(Suppl 45):S137. 

5^th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Geneva, Switzerland (April 15-18, 1998)

• Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32. 
• Rogers S, Mohs R, Friedhoff L, Doody RS. Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance? Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32. 

American Academy of Neurology (AAN)
49^th Annual Meeting in Boston, Mass. (April 15-17, 1997)

• Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, et al. Outcome measures in dementia trials-video CIBIC validity and reliability. Neurology. 1997;48(3):A233-A234. 

American College of Neuropsychopharmacology (ACNP)
35^th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996)

• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study. Presented at the American College of Neuropsychopharmacology (ACNP), 35^th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996).  

International Behavioral Neuroscience Society (ISBN)
5^th Annual Meeting in Cancun, Mexico (May 2-5, 1996)

• Kashani A, Doody RS, Wayner MJ, Phelix CF. Prevalence of uncontrolled hypertension in a population of Alzheimer's patients. Presented at the International Behavioral Neuroscience Society (ISBN), 5^th Annual Meeting in Cancun, Mexico (May 2-5, 1996).  

American Academy of Neurology (AAN)
48^th Annual Meeting in San Francisco, Calif. (March 23-30, 1996)

• Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, et al. Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment. Neurology. 1996;46(2):A403. 
• Rogers S, Doody RS, Mohs R, Friedhoff L. E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial. Neurology. 1996;46(2):A217. 
• Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH. Pharmacologic evidence for autonomic sudomotor dysfunction in patients with Alzheimer's disease. Neurology. 1996;46(2):A162. 

International Neuropsychological Society (INS)
24^th Annual Meeting in Chicago, Ill. (Feb. 14-17, 1996)

• Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, et al. Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials. Int J Neurosci. 1996;2:4. 

Gerontological Society of America (GSA)
50^th Annual Meeting in Los Angeles, Calif. (Nov. 15-19, 1995)

• Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, et al. A new clinical global rating scale for Alzheimer's clinical trials. Gerontologist. 1995;35(2):63. 

American Neuropsychiatric Association (ANPA)
7^th Annual Meeting in Pittsburgh, Penn. (Oct. 12-15, 1995)

• Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE. Estrogen and psychomotor performance. J Neuropsychiatry Clin Neurosci. 1995;7(3):410. 

American Academy of Neurology (AAN)
47^th Annual Meeting in Seattle, Wash. (May 6-13, 1995)

• Doody RS, Lynn P, Massman PJ. A calculated measure to predict rate of progression in Alzheimer's disease. Neurology. 1995;45(4 Suppl 4):A195. 

International Neuropsychological Society (INS)
23^rd Annual Meeting in Seattle, Wash. (Feb. 8-11, 1995)

• Massman PJ, Doody RS. Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men. Int J Neurosci. 1995;145. 

American Academy of Neurology (AAN)
46^th Annual Meeting in Washington, DC (May 1-7, 1994)

• Doody RS, Massman PJ, Nance ML. Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD). Neurology. 1994;44(4 Suppl 2):A196. 
• Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs. Neurology. 1994;44(4 Suppl 2):A194. 

International Neuropsychological Society (INS)
22^nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

• Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease. Int J Neurosci. 1994;43. 

American Neurological Association (ANA)
118^th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)

• Doody RS, Massman P. Dysfluency in the speech of AD patients. Ann Neurol. 1993;34(2):249. 
• Doody RS, Welsh K. Literacy and cognition in northern Thailand. Ann Neurol. 1993;34(2):249. 

American Society of Human Genetics (ASHG)
43^rd Annual Meeting in New Orleans, La. (Oct. 5-9, 1993)

• Dunn W, Doody RS, Gopnik M, Ashizawa T. Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia. Am J Hum Genet. 1993;53(Suppl):A1692. 

American Psychiatric Association (APA)
146^th Annual Meeting in San Francisco, Calif. (May 22-27, 1993)

• Kotrla K, Chacko R, Jhingran S, Doody RS. Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease. Presented at the American Psychiatric Association (APA), 146^th Annual Meeting in San Francisco, Calif. (May 22-27, 1993).  

International Neuropsychological Society (INS)
21^st Annual Meeting in Galveston , Texas (Feb. 24-27, 1993)

• Massman P, Doody RS. Correlates of asymmetric motor speed in Alzheimer's disease. J Clin Exp Neuropsychol. 1993;15:31. 

National Academy of Neuropsychology (NAN)
12^th Annual Meeting in Pittsburgh, Penn. (Nov. 5-7, 1992)

• Massman P, Doody RS. Neuropsychological correlates of apraxia in Alzheimer's disease patients. Arch Clin Neuropsychol. 1992;8:249-50. 

American Anthropological Association (AAA)
90^th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991)

• Doody RS. Positioning: Neurology and anthropology enabling practices. Presented at the American Anthropological Association (AAA), 90^th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991).   [View poster]

American Neurological Association (ANA)
116^th Annual Meeting in Seattle, Wash. (Sept. 28 - Oct. 2, 1991)

• Doody RS, Strittmatter WJ, Jhingran S. Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia. Ann Neurol. 1991;30(2):249-50. 
• Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F. Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery. Ann Neurol. 1991;30(2):285-6. 
• Mahurin R, Feher E, Doody RS, Inbody S. Positive and negative psychiatric symptoms in Alzheimer's disease. Ann Neurol. 1991;30(2):239. 

American Academy of Neurology (AAN)
43^rd Annual Meeting in Boston, Mass. (April 21-27, 1991)

• Doody RS, Jankovic J. The alien hand and related signs. Neurology. 1991;41(3 Suppl 1). 

American Anthropological Association (AAA)
89^th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990)

• Doody RS. Sense and nonsense: Dissemination and empiricism in practice. Presented at the American Anthropological Association (AAA), 89^th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990).   [View poster]

American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
37^th Annual Meeting in Chicago, Ill. (Sept. 7-8, 1990)

• Doody RS, Hrachovy RA. Recurrent posterior-type aphasia associated with a seizure focus. Electroencephalogr Clin Neurophysiol. 1991;79:28. 

American Academy of Neurology (AAN)
42^nd Annual Meeting in Miami, Fla. (April 2-4, 1990)

• Feher E, Doody RS, Whitehead J, Priozzolo F. Progressive nonfluent aphasia. Neurology. 1990;40(4 Suppl 1). 

American College of Cardiology (ACC)
31^st Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982)

• Ornish DM, Scherwitz LW, Doody RS, et al. Effects of stress management and dietary changes in treating ischemic heart disease. Presented at the American College of Cardiology (ACC), 31^st Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982).